bioAffinity Technologies, Inc. 近日宣布，其利用Cypath® Lung技术的新型肺癌检测方法已获得墨西哥专利许可通知。
这项专利授权覆盖了公司创新的肺癌检测技术，进一步巩固了其在癌症早期诊断领域的知识产权布局。Cypath® Lung技术旨在通过非侵入性方法，提升肺癌检测的准确性与可及性。
此次获得墨西哥专利许可，标志着该技术在全球范围内的知识产权保护取得又一重要进展。它为bioAffinity Technologies未来在墨西哥及更广泛拉丁美洲市场的商业拓展奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.